Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of ...

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...

Alumis is also developing another tyrosine kinase 2 blocker, A-005, for neuroinflammatory and neurodegenerative conditions ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Oppenheimer lowered the firm’s price target on Alumis (ALMS) to $26 from $32 and keeps an Outperform rating on the shares. The firm says the ...

Alumis (NASDAQ:ALMS – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 12th. Analysts expect the company to announce earnings of ($1.36) ...

In a report released today, Jeff Jones from Oppenheimer reiterated a Buy rating on Alumis Inc. (ALMS – Research Report), with a price target of ...

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders ...